William Blair Forecasts Higher Earnings for Twist Bioscience

Twist Bioscience Co. (NASDAQ:TWST) – Investment analysts at William Blair increased their Q2 2025 earnings per share (EPS) estimates for shares of Twist Bioscience in a note issued to investors on Tuesday, February 4th. William Blair analyst M. Larew now expects that the company will earn ($0.55) per share for the quarter, up from their prior forecast of ($0.57). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.27) per share. William Blair also issued estimates for Twist Bioscience’s Q3 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.07) EPS, Q1 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.49) EPS.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period last year, the company earned ($0.75) earnings per share. The company’s quarterly revenue was up 24.1% compared to the same quarter last year.

Other research analysts have also issued research reports about the stock. Scotiabank raised their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research note on Tuesday. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday. Robert W. Baird lifted their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, TD Cowen reiterated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $53.80.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $53.66 on Thursday. Twist Bioscience has a 52 week low of $27.41 and a 52 week high of $60.90. The company’s 50-day moving average price is $48.74 and its two-hundred day moving average price is $46.27.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, Director Robert Chess sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $47.26, for a total value of $170,136.00. Following the completion of the sale, the director now directly owns 21,641 shares of the company’s stock, valued at $1,022,753.66. The trade was a 14.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Dennis Cho sold 1,507 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00. Following the transaction, the insider now owns 91,163 shares in the company, valued at $4,375,824. This represents a 1.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 59,002 shares of company stock valued at $2,851,681 in the last quarter. Company insiders own 3.01% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently bought and sold shares of TWST. Van ECK Associates Corp lifted its position in shares of Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after buying an additional 267 shares during the last quarter. Signaturefd LLC raised its stake in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Twist Bioscience by 2.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock worth $734,000 after purchasing an additional 363 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the period. Finally, US Bancorp DE boosted its position in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after purchasing an additional 601 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.